Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?

Bristol Myers Squibb's Camzyos delivered five-year data showing 97.4% of patients with obstructive hypertrophic cardiomyopathy achieved target LVOT gradient reductions. The drug posted $729 million in first-half 2026 sales, up 74% year-over-year, underscoring its commercial momentum.

BMY is awaiting FDA approval to expand Camzyos into adolescent patients, with a decision deadline of September 30, 2026. Approval would open a new revenue stream in a high-unmet-need population.

Competition is tightening. Cytokinetics won FDA approval for Myqorzo in December 2025, marking the first direct rival in the space. CYTK's entry validates the market but fragments share. Edgewise Therapeutics is advancing EDG-7500 through clinical trials, adding a third potential entrant. EWTX's pipeline progress could further crowd the once-monopolistic Camzyos franchise.

The durability data supports BMY's positioning, but the approval timeline and competitive encroachment will define whether Camzyos sustains its growth trajectory or faces margin pressure.